We are live on ! Find out more
SONN

Sonnet BioTherapeutics
SONN

Delisted

SONN was delisted on the 2nd of December, 2025.

Back to rankings

8 hedge funds and large institutions have $1.02M invested in Sonnet BioTherapeutics in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 8 → 8 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

2% less capital invested

Capital invested by funds: $1.04M → $1.02M (-$19K)

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$121K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$38.1K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$38.1K
4
ASN
Advisory Services Network
Georgia
+$12.7K
5
BlackRock
BlackRock
New York
+$12.7K

Top Sellers

Rank Fund Capital Flow
1
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$63K
2
SSA
Schonfeld Strategic Advisors
New York
-$31K
3
IWM
IHT Wealth Management
Illinois
-$26K
4
RFA
Reilly Financial Advisors
California
-$14K
5
TRCT
Tower Research Capital (TRC)
New York
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$550K +$12.7K +2 +2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$303K +$121K +19 +53%
ASN
3
Advisory Services Network
Georgia
$55K +$12.7K +2 +25%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$35K +$38.1K +6 New
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$34K +$38.1K +6 New
MSFS
6
Main Street Financial Solutions
Pennsylvania
$24K +$25.4K +4 New
UBS Group
7
UBS Group
Switzerland
$13K +$12.7K +2 New
Morgan Stanley
8
Morgan Stanley
New York
$3K +$6.36K +1 New
IA
9
IFP Advisors
Florida
$2K – – –
SFI
10
Susquehanna Fundamental Investments
Pennsylvania
– -$63K -10 Closed
SSA
11
Schonfeld Strategic Advisors
New York
– -$31K -5 Closed
IWM
12
IHT Wealth Management
Illinois
– -$26K -4 Closed
RFA
13
Reilly Financial Advisors
California
– -$14K -2 Closed
TRCT
14
Tower Research Capital (TRC)
New York
– -$7K -1 Closed
JCM
15
Jacobi Capital Management
Pennsylvania
– -$1K – –

SONN Hedge Fund Activity: Q4 2020 in Review

8 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q4 2020, worth a combined $1.02M — down 1.8% from $1.04M a quarter earlier.

Fund positioning in SONN was balanced in Q4 2020: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $121K. The largest seller was Susquehanna Fundamental Investments, exiting entirely with an estimated $63K sold.

  • 8 institutional investors held Sonnet BioTherapeutics (SONN) as of Q4 2020, unchanged from Q3 2020.
  • Funds reported $1.02M of Sonnet BioTherapeutics stock for Q4 2020, down 1.8% quarter-over-quarter.
  • 5 funds opened new Sonnet BioTherapeutics positions in Q4 2020 and 5 closed out, a net change of 0 holders.
  • The largest Sonnet BioTherapeutics buyer in Q4 2020 was Vanguard Group, an estimated $121K added.
  • The largest Sonnet BioTherapeutics seller in Q4 2020 was Susquehanna Fundamental Investments, an estimated $63K sold.

Based on aggregated 13F filings for Q4 2020.